

REMARKS

Applicants request the entry of the changes in the specification requested above. It is believed that no new matter has been added by virtue of the amendments made to the specification.

With regard to the Figures, replacement Figures 3A through 3D are supported by original Figures 3A and 3B as filed. Replacement Figures 7A through 7D are supported by original Figures 7A and 7B as filed. Minor notational corrections are made with replacement Figure 8 to conform to standard restriction formatting.

Table 1 lists peptides synthesized based on the sequence of the human Her-2/neu protein wherein each sequence contained the anchor motif for HLA A2.1, that is, L, I, M, V, A, T at position 2 and position 8/9/10 (Rupert, J. *et al.* *Cell* (1993) 74:929-937). *See page 8, lines 25-27 of the specification.* The sequence corresponding with peptide H12 in Table 1 now reads "HLYQGCQVV". Those of skill in the art would recognize that as originally written, 'O' is not a standard abbreviation, that the sequence is too short, and that the sequence does not have L, I, M, V, A, T at position 8/9/10. The correct sequence is found in the Ruppert, *et al.* reference cited at page 8, lines 25-27 of the specification. Further, the Erb2 Human sequence (with Her2 and Neu listed as synonyms) was entered in Swiss-Prot and originally released on 05 August 1987. Still further, the c-erb-B-2 precursor (Homo sapiens) was available on-line on March 30, 1995.

Applicants submit herewith a revised Sequence Listing pages 1-20 to include as a revised sequence listing as part of this Application. The pages of the revised Sequence Listing are provided in both paginated and unpaginated format. Please enter the revised Sequence Listing and renumber the pages of the Sequence Listing along with those of the claims and the abstract accordingly.

Further enclosed is a computer readable copy of the above-mentioned copy of the Sequence Listing. That copy is the same as the copy of the Sequence Listing.

Also enclosed is a Statement in Support of Filing and Submissions in Accordance with 37 CFR 1.821-1.825, which declares that the content of the paper and the computer readable copies of the Sequence Listing submitted in accordance with 37 CFR 1.821 (c) and (e), respectively, are the same and that the submission, filed in accordance with 37 CFR 1.821 (g) does not introduce new matter.

The replacement Figures, Sequence Listing, and Table 1 are submitted to make them consistent with one another. Support for the present amendments can be found throughout the application including the claims and drawings as filed originally. No new matter has been added by virtue of the amendments.

If for any reason an additional fee is required, a fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. **04-1105**.

Respectfully submitted,

Date: January 6, 2003



Kathryn A. Piffat, Ph.D. (Reg. No. 34,901)
EDWARDS & ANGELL, LLP
P. O. Box 9169
Boston, MA 02209
Tel. (617) 439-4444
Fax (617) 439-4170

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The above-referenced application is amended as follows:

IN THE SPECIFICATION:

Please replace the paragraph on page 4, lines 1-3, with the following paragraph:

-- Figures 3A through 3D show[s] the complete nucleotide (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) of a single chain TCR derivative which contains variable α and β specific for HA linked through a short peptide linker and then fused through a CD8 hinge to the ζ chain. --

Please replace the paragraph on page 4, lines 11-12, with the following paragraph:

-- Figures 7A and 7B show the nucleotide sequence and deduced amino acid sequence of the variable regions of the α [and β] chains of H7-specific TCR [respectively]. Figures 7C and 7D show the nucleotide sequence and deduced amino acid sequence of the variable regions of the β chains of H7-specific TCR. --

On page 9, Table 1 is amended as follows:

Table 1. Her-2/neu peptides used for immunization				
PEPTIDE	SEQUENCE #	SEQUENCE	IMMUNOGENICITY	% INHIBITION
H3	369-377	KIFGSLAFL	+	38
H6	444-453	TLQGLGISWL	-	56
H7	773-782	VMAGVGSPYV	+	55
H8	546-555	VLQGLPREYV	-	43
H12	48-56	HLYQGC[O]QVV[W]	-	15
H13	689-697	RLLQETELV	-	56
H14	747-755	KIPVAIKVL	-	35
H15	789-797	CLTSTVQLV	-	33
H16	799-807	QLMPYGCLL	-	50
H17	851-859	VLVKSPNHV	-	12
H18	871-879	DIDETEHYA	-	37
H19	933-941	DLLEKGERL	-	36
H20	971-979	ELVSEFSRM	-	5
H21	971-980	ELVSEFSRMA	-	25
H22	972-980	LVSEFSRMA	-	14
H23	1016-1024	DLVDAEEYL	-	35
H24	1172-1180	TLSPGKNGV	-	57
HIV-9K	POL	KLVGKLNWA	+	80

RECEIVED
 MAY 14 2003
 TECH CENTER 1600/2900